What Cancer Screening Is Needed for Seronegative IMNM?

It is completely understandable to feel overwhelmed when your doctor orders cancer screenings right after you have been diagnosed with a rare muscle disease. The reason for these tests is that seronegative immune-mediated necrotizing myopathy (IMNM)—a subtype where the specific antibodies usually associated with the disease (anti-HMGCR and anti-SRP) are not found in your blood—has a potential, though not fully understood, association with underlying cancer ^[1][2]. Because of this possible link, an individualized cancer evaluation at or near the time of diagnosis is a standard part of your initial care ^[3].

The Immune System Connection

In some cases, autoimmune myopathies can act as a paraneoplastic syndrome ^[1]. This means that if an undetected cancer is present, the immune system may ramp up to fight it but mistakenly attack healthy muscle tissue instead.

However, it is important to know that the biological relationship is not fully understood, and evidence regarding cancer risk in seronegative IMNM is mixed and limited ^[2][4]. While one retrospective study found cancer in roughly 30% (11 out of 37) of its seronegative IMNM patients, other research suggests the risk may not be significantly higher than in the general population ^[5][6]. Ultimately, not everyone with seronegative IMNM has cancer. Age is a significant factor; the older you are at diagnosis, the more relevant these screenings become ^[5].

What Screenings to Expect

The International Myositis Assessment and Clinical Studies Group (IMACS) provides guidelines to help doctors tailor cancer screening based on your age, specific symptoms, and individual risk factors ^[3]. Rather than a one-size-fits-all approach, your team will decide between basic and enhanced screening panels.

Depending on your personalized risk, your evaluation may include:

Note: FDG stands for fluorodeoxyglucose, a safe radioactive sugar used in PET scans to show where cells are highly active.

What the Results Mean

Going through these tests can be stressful, but the goal is to identify any treatable conditions early while balancing the risks of over-testing.

If an underlying cancer is found: Treating the cancer can sometimes improve the muscle condition, but muscle weakness or inflammation may persist ^[7]. You will likely need coordinated care between an oncologist and a neuromuscular specialist, as you may still require separate treatments for the IMNM itself.

If your screenings come back clear: A negative workup lowers suspicion and provides reassurance, but no test can detect every cancer. It is crucial to continue discussing any new or persistent symptoms—such as unexplained weight loss, night sweats, or changes in bowel habits—with your doctor ^[3]. Follow-up screenings should be based on your individual risk category, as there is no universal schedule for ongoing testing in seronegative IMNM ^[3].

Talk to your doctor about how they classify your specific risk level, why each proposed test is appropriate for you, and what the follow-up plan will look like.